prikaz prve stranice dokumenta The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
  Download
PDF 94.16 KB
Other - Conference abstract
The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
Journal of Thoracic Oncology, 12 (2017), S1; S1283. https://doi.org/10.1016/j.jtho.2016.11.1814
Serdarevic, Marina; Kukulj, Suzana; Rebic, Ante; Drpa, Gordana; Budimir, Bernard; Popovic, Filip; Lovric, Tea; Sreter, Katherina; Samarzija, Miroslav

Cite this document

Serdarevic, M., Kukulj, S., Rebic, A., Drpa, G., Budimir, B., Popovic, F. ... Samarzija, M. (2017). The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes. Journal of Thoracic Oncology, 12. (S1), S1283. doi: 10.1016/j.jtho.2016.11.1814

Serdarevic, Marina, et al. "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes." Journal of Thoracic Oncology, vol. 12, no. S1, 2017, p. S1283. https://doi.org/10.1016/j.jtho.2016.11.1814

Serdarevic, Marina, Suzana Kukulj, Ante Rebic, Gordana Drpa, Bernard Budimir, Filip Popovic, Tea Lovric, Katherina Sreter and Miroslav Samarzija. "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes." Journal of Thoracic Oncology 12, no. S1 (2017): S1283. https://doi.org/10.1016/j.jtho.2016.11.1814

Serdarevic, M., et al. (2017) 'The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes', Journal of Thoracic Oncology, 12(S1), p. S1283. doi: 10.1016/j.jtho.2016.11.1814

Serdarevic M, Kukulj S, Rebic A, Drpa G, Budimir B, Popovic F, and sur.. The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes. Journal of Thoracic Oncology [Internet]. 2017 January [cited 2024 November 21];12(S1):S1283. doi: 10.1016/j.jtho.2016.11.1814

M. Serdarevic, et al., "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes", Journal of Thoracic Oncology, vol. 12, no. S1, p. S1283, January 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:485963. [Accessed: 21 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
AuthorMarina Serdarevic
AuthorSuzana Kukulj
AuthorAnte Rebic
MBZ: 92640
AuthorGordana Drpa
AuthorBernard Budimir
AuthorFilip Popovic
AuthorTea Lovric
AuthorKatherina Sreter
AuthorMiroslav Samarzija
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Lung cancer is often insidious disease. It usually produces only a few symptoms until the disease is advanced. At initial diagnosis 20% of patients have localized disease, 25% of patients have regional metastasis and 55% of patients have distant spread of disease. Metastasis is a process by which a small number of cancer cells undergo numerous alterations, which enables them to form secondary tumors at another and often multiple sites in the host. Recently, studies have suggested that cancer stem cells are the originators of metastasis. Cancer stem cells are small populations of slowly dividing, treatment – resistant, undifferentiated cancer cells that are being discovered in a different cancers. Metformin has proved to be effective in the treatment of glioblastomas and neuroblastomas, in vitro, by targeting their cancer stem cell population. Recently, studies have shown that metformin use is not associated with a decreased risk of lung cancer in patients with type 2 diabetes, but it has been suggested that metformin use is associated with improved survival among patients with stage IV NSCLC patients.
Languageenglish
Publication typeOther - Conference abstract
Publication statusPublished
Peer reviewUnknown
Publication versionPublished version
Journal titleJournal of Thoracic Oncology
Numberingvol. 12, no. S1, p. S1283
p-ISSN1556-0864
DOIhttps://doi.org/10.1016/j.jtho.2016.11.1814
URN:NBNurn:nbn:hr:220:485963
Publication2017-01
ConferenceTitle: IASLC 17th World Conference on Lung Cancer
Location: Vienna, Austria
Organizer: International association for the study of lung cancer
Start date: 2016-12-04
End date: 2016-12-07
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S1556086416330556
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-10-02 10:07:45